Clinical magnetic hyperthermia requires integrated magnetic particle imaging

Sean Healy, Andris F. Bakuzis, Patrick W. Goodwill, Anilchandra Attaluri, Jeff W.M. Bulte, Robert Ivkov

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Magnetic nanomaterials that respond to clinical magnetic devices have significant potential as cancer nanotheranostics. The complexities of their physics, however, introduce challenges for these applications. Hyperthermia is a heat-based cancer therapy that improves treatment outcomes and patient survival when controlled energy delivery is combined with accurate thermometry. To date, few technologies have achieved the needed evolution for the demands of the clinic. Magnetic fluid hyperthermia (MFH) offers this potential, but to be successful it requires particle-imaging technology that provides real-time thermometry. Presently, the only technology having the potential to meet these requirements is magnetic particle imaging (MPI), for which a proof-of-principle demonstration with MFH has been achieved. Successful clinical translation and adoption of integrated MPI/MFH technology will depend on successful resolution of the technological challenges discussed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > In Vivo Nanodiagnostics and Imaging.

Original languageEnglish (US)
Article numbere1779
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Issue number3
StatePublished - May 1 2022

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering


Dive into the research topics of 'Clinical magnetic hyperthermia requires integrated magnetic particle imaging'. Together they form a unique fingerprint.

Cite this